Biotechnology

Over 86 percent of Thai and Indonesian Women Consider Thalassemia Screening after Learning about Associated Health Risks

Thai (91.2%) and Indonesian (86.6%) women consider screening after learning about health risks and costs which is higher than the global average of 84.5% BANGKOK, Nov. 17, 2023 /PRNewswire/ -- According to Thailand's Ministry of Public Health , ...

2023-11-17 08:22 2091

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and ATG-037 (oral CD73 inhibitor) have shown clinical responses in cancer patients with advanced diseases. * ATG-008 (dual mTORC1/2 inhibitor) continued showing strong cli...

2023-11-17 08:00 2113

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial

SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children with achondroplasia (ACH) aged 2 to 10 years. In the trial, ...

2023-11-16 22:00 1561

Complete Genomics opens $3.2 million manufacturing facility at its San Jose headquarters

SAN JOSE, Calif., Nov. 16, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, today announced plans for the opening of a$3.2 million manufacturing facility within its headquarters in San Jose, California. The facility, scheduled to open inMarch 2024, will give Comple...

2023-11-16 22:00 1688

ACROBiosystems launches GMP-grade DLL4 Protein to accelerate stem cell manufacturing

NEWARK, Del., Nov. 16, 2023 /PRNewswire/ -- ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, recently announces the launch of GMP grade DLL4. GMP grade DLL4 is a recombinant, soluble form of Delta-like Ligand 4, or DLL4, ...

2023-11-16 20:08 1429

CU Medicine develops novel microbiome technology MOZAICTM for faecal microbiota transplantation

Enhancing treatment success for Clostridioides difficile infections to over 90% HONG KONG, Nov. 16, 2023 /PRNewswire/ -- Clostridioides difficile infection (CDI) is a common hospital-acquired infection worldwide. Recurrence and mortality rates have been reported to be up to 35% and 40%, respectiv...

2023-11-16 17:26 1902

Origin Agritech to Hold Business Update Conference Call on Tuesday, November 21 at 8 a.m. ET

BEIJING, Nov. 15, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, will host a conference call onTuesday, November 21, at 8:00 AM ET (9:00 PM Beijing Time) with the investment community to discuss the Company'...

2023-11-16 05:05 2122

The PolG Foundation awards over $3.5M in academic grants to pioneer POLG research

NEW YORK and PARIS, Nov. 15, 2023 /PRNewswire/ --The PolG Foundation is a nascent foundation established in 2022 by a PolG family, with the mission to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders.  To view the Multimedia News Release, p...

2023-11-15 20:42 1877

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Henlius(2696.HK)announced its financial results and business update for the first three quarters of 2023. As of September 30, 2023, Henlius generated a total revenue of RMB3.9278 billion, rising by 84.0% YoY, and a profit totaledRMB407.8 million, attributed ...

2023-11-15 20:16 2906

RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Lat...

2023-11-15 16:35 1832

Riding the tide, realize the future: The BD paths for Chinese Biotech

WUXI, China, Nov. 14, 2023 /PRNewswire/ -- 2023 BIO-Europe just closed last week. In line with previous conferences, this BD carnival attracted more than 2,000 companies, 5,000 attendees from close to 60 countries all over the world. Recently, we interviewed a global BD expert, Dr. Kaan Certel.  ...

2023-11-15 10:42 1277

2023 World Laureates Association Prize winners awarded in Shanghai

SHANGHAI, Nov. 14, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine onNov. 6 at the opening ceremony of the 6th WLA Forum hel...

2023-11-15 09:54 3812

BioDuro-Sundia Radioisotope Laboratory Technology Upgrades Accelerate Innovation

SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Radioisotope assays a microanalytical method that uses radionuclides as tracers to label research objects. Compared with conventional biological sample detection techniques, Radioisotope assay has distinct advantages such as high specificity, high sensitivi...

2023-11-15 09:00 1758

EDAN's Focus on Medical Technology Advancement Shines at MEDICA 2023

DUSSELDORF, Germany, Nov. 14, 2023 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, showcased its innovative range of new products at MEDICA 2023 inGermany. This grand event, anticipated to draw over 81,000 v...

2023-11-14 22:31 1732

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-11-14 21:30 1345

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited  (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore -based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherap...

2023-11-14 20:47 1166

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...

2023-11-14 08:27 1350

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1574

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...

2023-11-14 06:40 1926

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus ...

2023-11-14 02:00 2832
1 ... 67686970717273 ... 306

Week's Top Stories